Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01741142 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of ABT-436 in Major Depressive Disorder
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT01741142: Clinical Trial Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
NCT01741142 is a Phase 2 study that was terminated before completion, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 19 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01741142, a Phase 2 study, was terminated before completion, sponsored by AbbVie (prior sponsor, Abbott).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose is to study the efficacy and safety of ABT-436 in Major Depressive Disorder.
Primary Outcome
Primary efficacy variable will be change from baseline to Week 6 visit on Montgomery-Asberg Depression Rating Scale (MADRS) total score.
Interventions
- DRUG Placebo
- DRUG Escitalopram
- DRUG ABT-436
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-01 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Why NCT01741142 stopped before completion
NCT01741142 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01741142 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01741142 about?
NCT01741142 is a clinical study titled "Efficacy and Safety Study of ABT-436 in Major Depressive Disorder". The purpose is to study the efficacy and safety of ABT-436 in Major Depressive Disorder.
What is the current status of trial NCT01741142?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2012-01. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01741142?
The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG), ABT-436 (DRUG).
Who is sponsoring clinical trial NCT01741142?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01741142's enrollment target sits among peer trials
19 1894th of 2000 higher than 103 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia